Alcon AG | ALC - Cash And Equivalent


Alcon AG reported $1.58B in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
AstraZeneca USD 7.56B 1.85B Mar/2026
Bayer EUR 6.67B 774M Dec/2025
Essilor EUR 3.54B 758M Dec/2025
Fresenius EUR 1.31B 81M Dec/2025
Fresenius Medical Care EUR 1.24B 343.37M Mar/2026
GlaxoSmithKline GBP 3.44B 292M Mar/2026
GRIFOLS EUR 801M 242.31M Dec/2025
Lonza CHF 719M 188M Dec/2025
Merck EUR 2.33B 77M Dec/2025
Novartis USD 6.88B 4.56B Mar/2026
Philips EUR 2.79B 882M Dec/2025
Roche Holding CHF 7.55B 579M Jun/2025
Sanofi EUR 7.66B 1.25B Dec/2025
Sonova Holding CHF 413.9M 134.3M Jun/2023
UCB EUR 1.57B 1.14B Dec/2024